IV - 医索

找到约 1019 条结果

Phase lalb trial of zongertinib (Bl 1810631),aHER2-specific tyrosine kinase inhibitor in patients withHER2 aberration-positive solid tumors updatedPhase la data from Beamion LUNG-1, includingprogression-

医客学院 - 会议报告集

Outcomes with Perioperative Durvalumab in Patientswith Resectable NSCLc and Baseline N2 Lymph NodeInvolvement(N2 R-NSCLC)

医客学院 - 会议报告集

NRG-LU002Randomized Phase lllll Trial Of MaintenanceSystemic Therapy Versus Local Consolidative Therapy (LCT) Plus Maintenance Systemic Therapy For Limited Metastatic Non-Small Cell Lung Cancer

医客学院 - 会议报告集

Niraparib and Dostarlimab efficacy in patients with platinum.sensitive relapsed mesothelioma MlST5, a phase lla clinicaltrial

医客学院 - 会议报告集

Neoadjuvant nivolumab plus chemotherapy vschemotherapy in patients with resectable NSCLC4-year update from CheckMate 816

医客学院 - 会议报告集

Lorlatinib vs Crizotinib in Treatment-NaivePatients With Advanced ALK Non-SmallCell Lung Cancer 5-Year Progression-FreeSurvival and Safety From the CRoWN Study

医客学院 - 会议报告集

Lorlatinib in TKl naive, advanced RoS1-positivenon-small cell lung cancer a multicenter, open-label, single-arm, phase 2 trial

医客学院 - 会议报告集

Ivonescimab combined with chemotherapy in patientswith EGFR-mutant non-squamous non-small cell lungcancer who progressed on EGFR-TKls treatment arandomized, double-blind, multi-center, phase 3 trial(HARM

医客学院 - 会议报告集

Health-Related Quality of Life Outcomes From the Randomized, Double-Blind Phase 3 KEYNOTE-671 Study of Perioperative Pembrolizumab for Early-Stage NSCLC

医客学院 - 会议报告集

Global Retrospective Study Comparing Consolidation ALK TKl to Durvalumab or Observation after Chemoradiation in Unresectable Locally Advanced ALK NSCLC

医客学院 - 会议报告集

今日实时热搜